[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518101":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":40,"locations":47,"responsibleParty":74,"collaborators":45,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":79,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":45,"studyType":91,"phases":92,"briefSummary":95,"conditions":96,"keywords":100,"overallStatus":50,"whyStopped":45,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Ministry of Health, Saudi Arabia","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Caffeine citrate group","EXPERIMENTAL","Infants receive either caffeine citrate in loading dose 20 mg\u002Fkg (equivalent for 10 mg\u002Fkg caffeine base) and maintenance dose 10 mg\u002Fkg\u002Fday (equivalent for 5 mg\u002Fkg caffeine base).",[13],"Drug: Caffeine citrate",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","PLACEBO_COMPARATOR","Infants received equivalent volume of saline.",[19],"Other: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Caffeine citrate","Caffeine citrate in loading dose 20 mg\u002Fkg (equivalent for 10 mg\u002Fkg caffeine base) and maintenance dose 10 mg\u002Fkg\u002Fday (equivalent for 5 mg\u002Fkg caffeine base)",[9],[27],"Intervention group",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"OTHER","Placebo","Equivalent volume of saline",[15],[34],"Saline",[36],{"name":37,"affiliation":38,"role":39},"Nehad Nasef","Neonatology Consultant","PRINCIPAL_INVESTIGATOR",[41],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Ohoud Almoualled, Dr","CONTACT","+966500550679",null,"o.doc2or@gmail.com",[48,68],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"King Salman Bin Abdulaziz Medical City","RECRUITING","Madinah","Medina Region","42319","Saudi Arabia","SA",{"type":57,"coordinates":58},"Point",[59,60],39.61417,24.46861,{"lat":60,"lon":59},[63,67],{"name":64,"role":43,"phone":65,"phoneExt":45,"email":66},"Yasmeen T Aljhani","+966148499629","med-ksamc-irb@moh.gov.sa",{"name":37,"role":39,"phone":45,"phoneExt":45,"email":45},{"facility":49,"status":50,"city":51,"state":45,"zip":45,"country":54,"countryCode":55,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},{"type":57,"coordinates":70},[59,60],{"lat":60,"lon":59},[73],{"name":64,"role":43,"phone":65,"phoneExt":45,"email":66},{"type":39,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":45,"oldOrganization":45},"Fatema Sulaiman Alhazmi","NICU Director","100518101","phase-2-caffeine-as-an-adjuvant-therapy-for-late-preterm-infants-with-respiratory-distress-100518101",false,"NCT06026163","Caffeine as an Adjuvant Therapy for Late Preterm Infants With Respiratory Distress","Caffeine for Late Preterm Infants: A Double Blind Randomized Controlled Trial","CAT\u002FLPT","Inclusion Criteria:\n\n* Newborn infants at gestational age 34 0\u002F7 through 36 6\u002F7\n* Presented with respiratory distress\n* Require respiratory support in the form of any of the following :\n\nA) Invasive mechanical ventilation, B) Non-invasive positive pressure ventilation, C) Nasal cannula with FIO2 requirement over 50% to keep pre-ductal saturation between 90-95%.\n\nExclusion Criteria:\n\n1 - Late preterm admitted for non-respiratory etiologies 2- Late preterm infants requiring nasal cannula on less than 50% FIO2 by 4 hours of age as they are less likely to require respiratory support for a long time.\n\n3- Newborn infants with congenital malformations and chromosomal anomalies. 4- Infants with echocardiographic evidence of PPHN requiring medical intervention.\n\n5- Late preterm with history of maternal substance abuse","ALL","1 Day","3 Days",{"count":89,"type":90},134,"ESTIMATED","INTERVENTIONAL",[93,94],"PHASE2","PHASE3","Use of caffeine citrate in late-preterm infants with respiratory distress is questionable. Oliphant and colleagues found in a recently published study that caffeine therapy use in late-preterm infants at a loading dose of 20 and 40 mg\u002Fkg and maintenance dose of 10 and 20 mg\u002Fkg\u002Fday reduces the incidence of intermittent hypoxia events by 61 and 67% respectively.\n\nThe investigators hypothesized that caffeine will improve respiratory drive, prevent apnea, shorten the hospital stay and improve arousal state in late preterm infants.\n\nThe investigators aim to study the effect of caffeine citrate on late preterm babies as regard duration of respiratory support, duration of hospital stay, respiratory morbidity, incidence and frequency of apnea.",[97,98,99],"Prematurity","Respiratory Disease","Ventilator Lung; Newborn",[101,102,103,104],"caffeine","preterm","newborn","respiratory support","2025-06-24",{"date":107,"type":108},"2025-06-27","ACTUAL",{"date":110,"type":108},"2023-10-12",{"date":112,"type":90},"2028-01-01",{"name":5,"class":6},2]